The earnings call reflects a positive outlook for Gilead with significant achievements, including the FDA approval of Yeztugo and strong sales growth in the HIV segment. However, there are challenges with declining Veklury sales and competition in cell therapy, along with potential policy impacts. Overall, the highlights significantly outweigh the lowlights, indicating a strong position for Gilead moving forward.

Company Guidance

During Gilead's Second Quarter 2025 Earnings Conference Call, the company announced an increase in its full-year revenue and EPS guidance, driven by strong commercial execution and operating expense discipline. Excluding Veklury, base business sales were $6.9 billion, showing a 4% year-over-year growth. Product sales reached $7.1 billion, up 2% from the previous year. HIV sales were robust, with a 7% increase year-over-year, led by Biktarvy sales of $3.5 billion, up 9%, and Descovy sales of $653 million, up 35%. The company also highlighted the successful launch of Yeztugo, with promising early feedback and a goal of achieving 75% access within six months. Gilead expects total product sales, excluding Veklury, to be in the range of $27.3 billion to $27.7 billion for the year, with an EPS range of $7.95 to $8.25.

FDA Approval of Yeztugo

Yeztugo, a twice-yearly injectable for HIV prevention, received FDA approval, marking a milestone in HIV treatment and prevention. The launch has seen high early uptake and awareness among healthcare providers.

Strong HIV Sales Growth

HIV product sales grew 7% year-over-year, driven by demand for Biktarvy and Descovy, which saw 9% and 35% growth respectively.

Positive Clinical Developments

Back-to-back positive Phase III results for Trodelvy in metastatic triple-negative breast cancer were announced, emphasizing its potential in first-line treatment settings.

Increased Revenue and EPS Guidance

Due to strong performance, Gilead has increased its revenue and EPS guidance for the full year.

Gilead Sciences (GILD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GILD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	2.16 / -	2.02	―	―	―
Aug 07, 2025	2025 (Q2)	1.96 / 2.01	2.01	0.00% (0.00)
Apr 24, 2025	2025 (Q1)	1.78 / 1.81	-1.32	237.12% (+3.13)
Feb 11, 2025	2024 (Q4)	1.74 / 1.90	1.72	10.47% (+0.18)
Nov 06, 2024	2024 (Q3)	1.53 / 2.02	2.29	-11.79% (-0.27)
Aug 08, 2024	2024 (Q2)	1.61 / 2.01	1.34	50.00% (+0.67)
Apr 25, 2024	2024 (Q1)	-1.49 / -1.32	1.37	-196.35% (-2.69)
Feb 06, 2024	2023 (Q4)	1.76 / 1.72	1.67	2.99% (+0.05)
Nov 07, 2023	2023 (Q3)	1.92 / 2.29	1.9	20.53% (+0.39)
Aug 03, 2023	2023 (Q2)	1.64 / 1.34	1.58	-15.19% (-0.24)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GILD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$110.28	$119.41	+8.28%
Apr 24, 2025	$105.40	$102.44	-2.81%
Feb 11, 2025	$94.80	$101.87	+7.46%
Nov 06, 2024	$89.66	$95.73	+6.77%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Gilead Sciences (GILD) report earnings?

Gilead Sciences (GILD) is schdueled to report earning on Oct 23, 2025, After Close (Confirmed).

What is Gilead Sciences (GILD) earnings time?

Gilead Sciences (GILD) earnings time is at Oct 23, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is GILD EPS forecast?

GILD EPS forecast for the fiscal quarter 2025 (Q3) is 2.16.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing